Literature DB >> 18611515

Quinolones in the treatment of uncomplicated urinary tract infections.

R R Bailey1.   

Abstract

In comparative clinical studies the quinolones have been shown to be effective in a short-course (3-5 days) or a single dose therapy in uncomplicated urinary tract infections. Comparative clinical trials of single dose therapy with the fluoroquinolones and trimethoprim or co-trimoxazole (trimethoprim/ sulfamethoxazole) for acute bacterial cystitis have shown equivalent efficacy. Studies on the use of quinolones for the treatment of uncomplicated acute pyelonephritis have also been reviewed. The results from several comparative trials which compared the fluoroquinolones with netilmicin, co-trimoxazole, cefadroxil, or ceftazidime have been comparable. Some of the fluoroquinolones can be administered in parenteral and oral forms enabling the patient to be discharged from hospital earlier, a more cost-effective option. The fluoroquinolones, in particular norfloxacin, have also been shown to be effective as prophylactic agents for patients with recurrent symptomatic urinary tract infections. The optimal dosage and length of prophylactic treatment have not yet been clearly defined.

Entities:  

Year:  1992        PMID: 18611515     DOI: 10.1016/0924-8579(92)90023-k

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.

Authors:  Gareth Lewis; Albert Juhasz; Euan Smith
Journal:  Environ Sci Pollut Res Int       Date:  2012-02-04       Impact factor: 4.223

2.  Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.

Authors:  Steven Simoens; Jan Verhaegen; Pascal van Bleyenbergh; Willy E Peetermans; Marc Decramer
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

Review 3.  Management of lower urinary tract infections.

Authors:  R R Bailey
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 4.  Quinolone antibacterials. An update of their pharmacology and therapeutic use.

Authors:  N von Rosenstiel; D Adam
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.